| HOME >> MEDICINE >> TECHNOLOGY |
Gemin X is currently conducting several clinical trials of obatoclax (GX15-070) in multiple cancer types as a combination therapy and as a single agent. In addition to the Phase 1b trial in MCL, Gemin X recently initiated a Phase 1/2 clinical trial in combination with docetaxel in patients with non-small cell lung cancer. Obatoclax (GX15-070) is also in Phase 2 clinical trials in patients with Hodgkin's Lymphoma, myelofibrosis with myeloid metaplasia, myelodysplastic syndrome, and follicular lymphoma both as single agent and in combination with rituximab. In multiple Phase 1 studies, obatoclax (GX15-070) was well-tolerated and resulted in clinical and biological activity.
About Mantle Cell Lymphoma (MCL)
Mantle cell lymphoma (MCL) belongs to a group of diseases known as non-Hodgkin's lymphomas, which are related cancers that affect the lymphatic system. Mantle cell lymphoma is an aggressive B-cell lymphoma that historically has been resistant to current standard chemotherapeutic approaches, making it a difficult cancer to treat. The median survival time is three years and the ten-year survival rate is only 5-10%.
Gemin X Biotechnologies Inc. specializes in the discovery and
development of novel small molecule cancer therapeutics based on
the regulation of apoptosis, the body's natural ability to destroy
injured or damaged cells. Gemin X's lead product, obatoclax
(GX15-070), is a small molecule, pan-inhibitor of Bcl-2
pro-survival proteins and is currently in Phase 2 clinical trials.
Gemin X is also developing a small molecule that induces apoptosis
in p53-defective cancers. Gemin X is privately hel
'"/>